Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. 19 \~ 79 years old~2. Patients who confirmed hypercholesterolemia.~3. Patients who requiring drug therapy according to NCEP ATP(National Cholesterol Education Program Adult Treatment Panel) III Guideline at Visit2.~4. Patients with Triglyceride\< 400 at Visit 2.~5. Patients who have a wash-out period over 4 weeks for other drugs that can affect lipid profile.(Patients who have lipid regulators should have washout period over six weeks)~6. Patients who agreed to participate in the trial~Exclusion Criteria:~1. Patients who have a history of myopathy or rhabdomyolysis by statin treatment or hypersensitivity to statin HMG CoA(3-hydroxy-3-methylglutaryl-coenzyme) reductase inhibitors) or ezetimibe.~2. A heavy alcohol consumer. (alcohol \> 25 units/week)~3. Patients with severe renal disease. (creatinine ≥ 2.0 mg/dL)~4. Patients with active liver disease and AST(aspartate transaminase) or ALT(alanine transaminase) \> 2 times of upper limit of normal range.~5. Patients with CPK(creatine phosphokinase) \> 2 x upper limit of normal range.~6. Patients who have a endocrine or metabolic diseases known to affect the serum phospholipid or lipoprotein.~7. Patients with HIV(human immunodeficiency virus positive.~8. Patients who have a acute arteriopathy.~9. Patients with uncontrolled hypertension.~10. Patients who have hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.~11. Patients who have a drugs absorption disorder by gastrointestinal surgery or gastrointestinal disorder.~12. Patients with tumor.~13. Patients who have hormonal therapy.~14. Pregnancy or breastfeeding patients who don't agree to use adequate contraception.~15. Patients who are judged unsuitable to participate in this study by investigator.~16. Patients taking other clinical trial drugs within 30 days from the time of visit for screening.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- R5 (Type: ACTIVE_COMPARATOR): Rosuvastatin 5mg
- R10 (Type: ACTIVE_COMPARATOR): Rosuvastatin 10mg
- R20 (Type: ACTIVE_COMPARATOR): Rosuvastatin 20mg
- R5/E10 (Type: EXPERIMENTAL): Rosuvastatin 5mg/Ezetimibe 10mg
- R10/E10 (Type: EXPERIMENTAL): Rosuvastatin 10mg/Ezetimibe 10mg
- R20/E10 (Type: EXPERIMENTAL): Rosuvastatin 20mg/Ezetimibe 10mg

Based on this trial design, predict the completion outcome and termination type (if applicable).